Read More

Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation By FDA Of Investigational New Drug (IND) Application For NP-300, A Novel Drug Candidate For Symptomatic Relief And Treatment Of Diarrhea From Cholera And Other Pathogens

 Napo Pharmaceuticals, Inc. ("Napo"), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the activation by the U.S. Food and

JAGX